Clinical performance of a commercially available thymidine kinase 1 assay for diagnosis of lymphoma in 42 hospitalized horses (2017-2020).
Abstract: Antemortem definitive diagnosis of lymphoma in horses is often difficult. Thymidine kinase 1 (TK1) assay is a potentially useful biomarker for lymphoma in horses. Objective: To report the clinical performance of a commercially available TK1 assay for diagnosis of lymphoma in horses. We hypothesized that there would be no association between serum TK1 activity and a diagnosis of lymphoma in horses. Methods: Forty-two hospitalized horses, 14 with a definitive diagnosis of lymphoma, 4 with other neoplasia, and 24 with inflammatory disease. Methods: Retrospective medical record review, groups were compared via Kruskal-Wallis and Mann-Whitney tests, and logistic regression was performed. Results: Median (range) TK1 was 3 U/L (0.4-17.7 U/L) in horses with lymphoma and 3.9 U/L (0.8-94 U/L) in horses without lymphoma (P = .59). There was no significant difference in total protein between horses with and without lymphoma (6.6 g/dL [5.5-8.3 g/dL] vs 6.6 g/dL [4.7-10.4 g/dL]; P = .83). There was no significant difference in fibrinogen between horses with and without lymphoma (447 [100-1364] mg/dL vs 433 [291-2004] mg/dL; P = .47). On logistic regression, serum TK1 activity was not associated with a diagnosis of lymphoma (odds ratio, 0.97; 95% confidence interval, 0.9-1.05, P = .48). Conclusions: Serum TK1 values were not predictive of lymphoma diagnosis in this cohort of horses.
© 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Publication Date: 2021-08-06 PubMed ID: 34359096PubMed Central: PMC8478028DOI: 10.1111/jvim.16239Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Biomarkers
- Clinical Findings
- Clinical Pathology
- Clinical Study
- Comparative Study
- Diagnosis
- Diagnostic Technique
- Disease
- Disease Diagnosis
- Equine Health
- Horses
- Hospitalization
- Inflammatory Response
- Lymphoma
- Neoplasm
- Regression Analysis
- Retrospective Study
- Serum
- Veterinary Medicine
- Veterinary Practice
- Veterinary Research
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research attempted to determine the efficacy of a commercially available assay for thymidine kinase 1 (TK1), a potential biomarker for lymphoma in horses. However, the study found no statistically significant relationship between serum TK1 activity and the occurrence of lymphoma.
Study Design and Methodology
- This study involved forty-two hospitalised horses; fourteen of which had a definitive diagnosis of lymphoma, four of which had other forms of neoplasia and the remaining twenty-four diagnosed with inflammatory disease. The categorization into these groups was based on a retrospection of the medical records available for each horse.
- The TK1 levels were measured in all the horses and the groups were compared using Kruskal-Wallis and Mann-Whitney tests. This was to determine any difference in the distribution of TK1 activity within these groups.
- Further statistical analysis using logistic regression was carried out to ascertain any potential association between serum TK1 activity and the diagnosis of lymphoma in horses.
Research Findings
- The median TK1 levels were found to be 3 U/L ranging between 0.4 and 17.7 U/L for horses with lymphoma and 3.9 U/L ranging between 0.8 and 94 U/L for horses without lymphoma.
- Further, the study found no significant difference in total protein and fibrinogen levels between horses with and without lymphoma. The data signifies that these biological parameters alone cannot be relied upon in the diagnosis of lymphoma.
- More importantly, the logistic regression analysis revealed no association between serum TK1 activity and a diagnosis of lymphoma in horses, further confirming the initial hypothesis of the study.
Conclusion
- Based on this study’s findings, the researchers concluded that the serum TK1 values do not predict a lymphoma diagnosis in horses.
- This significance of this study is that it challenges the efficacy of a commercially available TK1 assay as a definitive diagnostic tool for lymphoma in horses, suggesting the need for more comprehensive or alternative diagnostic strategies.
Cite This Article
APA
Moore C, Stefanovski D, Luethy D.
(2021).
Clinical performance of a commercially available thymidine kinase 1 assay for diagnosis of lymphoma in 42 hospitalized horses (2017-2020).
J Vet Intern Med, 35(5), 2495-2499.
https://doi.org/10.1111/jvim.16239 Publication
Researcher Affiliations
- Department of Clinical Studies, University of Pennsylvania, Kennett Square, Pennsylvania, USA.
- Department of Clinical Studies, University of Pennsylvania, Kennett Square, Pennsylvania, USA.
- Large Animal Clinical Sciences, University of Florida College of Veterinary Medicine, Gainesville, Florida, USA.
MeSH Terms
- Animals
- Biomarkers, Tumor
- Horse Diseases / diagnosis
- Horses
- Lymphoma / diagnosis
- Lymphoma / veterinary
- Retrospective Studies
- Thymidine Kinase
Conflict of Interest Statement
Authors declare no conflict of interest.
References
This article includes 21 references
- Knowles EJ, Tremaine WH, Pearson GR, Mair TS. A database survey of equine tumours in the United Kingdom.. Equine Vet J 2016;48(3):280‐284.
- Durham AC, Pillitteri CA, San Myint M. Two hundred three cases of equine lymphoma classified according to the World Health Organization (WHO) classification criteria.. Vet Pathol 2013;50(1):86‐93.
- Larsdotter S, Nostell K, von Euler H. Serum thymidine kinase activity in clinically healthy and diseased horses: a potential marker for lymphoma.. Vet J 2015;205(2):313‐316.
- von Euler H, Einarsson R, Olsson U. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease.. J Vet Intern Med 2004;18(5):696‐702.
- Hallek M, Wanders L, Strohmeyer S, Emmerich B. Thymidine kinase: a tumor marker with prognostic value for non‐Hodgkin's lymphoma and a broad range of potential clinical applications.. Ann Hematol 1992;65(1):1‐5.
- Hannigan BM, Barnett YA, Armstrong DB. Thymidine kinases: the enzymes and their clinical usefulness.. Cancer Biother 1993;8(3):189‐197.
- Taylor SS, Dodkin S, Papasouliotis K. Serum thymidine kinase activity in clinically healthy and diseased cats: a potential biomarker for lymphoma.. J Feline Med Surg 2013;15(2):142‐147.
- Von Euler HP, Rivera P, Aronsson A‐C. Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity—evaluation of a new, fully automated non‐radiometric assay.. Int J Oncol 2009;34(2):505‐510.
- Bagegni N, Thomas S, Liu N. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin‐dependent kinase 4/6 inhibition in patients with early‐stage breast cancer receiving neoadjuvant palbociclib.. Breast Cancer Res 2017;19(1):123.
- Elliott JW, Cripps P, Blackwood L. Thymidine kinase assay in canine lymphoma.. Vet Comp Oncol 2013;11(1):1‐13.
- Mouantri JP. Use of feline TK1 as a biomarker in disease monitoring.. Swedish University of Agricultural Sciences Library; 2013, 31.
- Zhou J, He E, Skog S. The proliferation marker thymidine kinase 1 in clinical use.. Mol Clin Oncol 2013;1(1):18‐28.
- Selting KA, Sharp CR, Ringold R, Knouse J. Serum thymidine kinase 1 and C‐reactive protein as biomarkers for screening clinically healthy dogs for occult disease.. Vet Comp Oncol 2015;13(4):373‐384.
- von Euler HP, Ohrvik AB, Eriksson SK. A non‐radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs.. Res Vet Sci 2006;80:17‐24.
- Norsworthy GD, Estep JS, Hollinger C. Prevalence and underlying causes of histologic abnormalities in cats suspected to have chronic small bowel disease: 300 cases (2008–2013).. J Am Vet Med Assoc 2015;247(6):629‐635.
- Tanaka K, Sishido T, Morimoto M, Inoue S, Takamura Y, Masumura M. Elevated serum thymidine kinase activity in patients with acute viral hepatitis.. Gastroenterol Jpn 1993;28(1):51‐55.
- Miglio A, Morelli C, Gialletti R. Clinical and immunophenotypic findings in 4 forms of equine lymphoma.. Can Vet J 2019;60(1):33‐40.
- Luethy D, Frimberger AE, Bedenice D. Retrospective evaluation of clinical outcome after chemotherapy for lymphoma in 15 equids (1991‐2017).. J Vet Intern Med 2019;33(2):953‐960.
- Chen ZH, Huang SQ, Wang Y. Serological thymidine kinase 1 is a biomarker for early detection of tumours—a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay.. Sensors 2011;11(12):11064‐11080.
- Evans SE, Bonczynski JJ, Broussard JD, Han E, Baer KE. Comparison of endoscopic and full‐thickness biopsy specimens for diagnosis of inflammatory bowel disease and alimentary tract lymphoma in cats.. J Am Vet Med Assoc 2006;229(9):1447‐1450.
- Taylor S, Pusterla N, Vaughan B. Intestinal neoplasia in horses.. J Vet Intern Med 2006;20:1429‐1436.
Citations
This article has been cited 1 times.- Drozdzewska K, Gehlen H. Markers for internal neoplasia in the horse. Vet Med Sci 2023 Jan;9(1):132-143.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
